Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip Dubovsky

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Vaccine|April 23, 2013
Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccineChin-Fen Yang, C Kathy Wang, Elissa Malkin, et al.
Vaccine|April 19, 2011
Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancerNatasha Halasa, Janet A Englund, Sharon Nachman, et al.
Plos One|November 9, 2013
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageElissa Malkin, Ram Yogev, Nazha Abughali, et al.
Clinical and Vaccine Immunology : CVI|July 7, 2017
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune ResponsesJudith Falloon, H Keipp Talbot, Craig Curtis, et al.
Vaccine|July 7, 2005
Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaquesJan A M Langermans, Annette Schmidt, Richard A W Vervenne, et al.
The Journal of Infectious Diseases|May 21, 2023
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary VaccinationLouis Fries, Neil Formica, Raburn M Mallory, et al.
Science Translational Medicine|December 21, 2022
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccineLauren A Chang, Emily Phung, Michelle C Crank, et al.
The New England Journal of Medicine|July 30, 2020
Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsM Pamela Griffin, Yuan Yuan, Therese Takas, et al.
Scientific Reports|November 6, 2023
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variantsNita Patel, Jessica F Trost, Mimi Guebre-Xabier, et al.
Vaccine|June 4, 2023
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Vaccine|April 23, 2013
Implication of respiratory syncytial virus (RSV) F transgene sequence heterogeneity observed in Phase 1 evaluation of MEDI-534, a live attenuated parainfluenza type 3 vectored RSV vaccineChin-Fen Yang, C Kathy Wang, Elissa Malkin, et al.
Vaccine|April 19, 2011
Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancerNatasha Halasa, Janet A Englund, Sharon Nachman, et al.
Plos One|November 9, 2013
Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of ageElissa Malkin, Ram Yogev, Nazha Abughali, et al.
Clinical and Vaccine Immunology : CVI|July 7, 2017
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune ResponsesJudith Falloon, H Keipp Talbot, Craig Curtis, et al.
Vaccine|July 7, 2005
Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaquesJan A M Langermans, Annette Schmidt, Richard A W Vervenne, et al.
The Journal of Infectious Diseases|May 21, 2023
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary VaccinationLouis Fries, Neil Formica, Raburn M Mallory, et al.
Science Translational Medicine|December 21, 2022
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccineLauren A Chang, Emily Phung, Michelle C Crank, et al.
The New England Journal of Medicine|July 30, 2020
Single-Dose Nirsevimab for Prevention of RSV in Preterm InfantsM Pamela Griffin, Yuan Yuan, Therese Takas, et al.
Scientific Reports|November 6, 2023
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variantsNita Patel, Jessica F Trost, Mimi Guebre-Xabier, et al.
Vaccine|June 4, 2023
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373Katia Alves, Joyce S Plested, Shirley Galbiati, et al.
Pageof 6